diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6016diaendo-6016Research ArticleСтатьиArticlesРоль апоптоза в патогенезе сахарного диабета 1 типаThe role of apoptosis in pathogenesis of type 1 diabetes mellitusПекареваЕлена ВладимировнаPekarevaElena Vladimirovnapekarevaev@mail.ruНиконоваТатьяна ВасильевнаNikonovaTatiana Vasil'evna-СмирноваОльга МихайловнаSmirnovaOlga Mikhailovna-ФГУ Эндокринологический научный центр, МоскваEndocrinological Research Centre, Moscow201015032010131№1 (2010)4549Copyright © Пекарева Е.В., Никонова Т.В., Смирнова О.М., 20102010Пекарева Е.В., Никонова Т.В., Смирнова О.М.Pekareva E.V., Nikonova T.V., Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6016

Сахарный диабет 1 типа (СД1) характеризуется прогрессирующей деструкцией ?-клеток поджелудочной железы. Ведущая роль в раз-рушении ?-клеток при СД1 отводится апоптозу. В данной статье рассмотрены основные пути активации апоптотического процесса,возможная роль апоптоза в регуляции иммунных механизмов, имеющих место в патогенезе СД1.

Type 1 diabetes mellitus (DM1) is known to be associated with progressive destruction of pancreatic beta-cells. Apoptosis plays the key role in this destructiveprocess. The paper focuses on major mechanisms underlying activation of beta-cell apoptosis and its role in regulation of immune processes inpatients with DM1.

апоптозсахарный диабет 1 типаFasFasLapoptosistype 1 diabetes mellitusFasFasLReferencesDe Franco S., Bonissoni S., Cerutti F. et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases // Diabetes. - 2001. - Vol. 50. - P. 483-488.De Franco S., Bonissoni S., Cerutti F. et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases // Diabetes. - 2001. - Vol. 50. - P. 483-488.De Franco S., Chiocchetti A., Ferretti M. et al. Defective function of the Fas apoptotic pathway in type 1 diabetes mellitus correlates with age at onset // Int. J. Immunopathol. Pharmacol. - 2007. - Vol. 20. - P. 567-576.De Franco S., Chiocchetti A., Ferretti M. et al. Defective function of the Fas apoptotic pathway in type 1 diabetes mellitus correlates with age at onset // Int. J. Immunopathol. Pharmacol. - 2007. - Vol. 20. - P. 567-576.Cohen J.J., Duke R.C., Fadok V.A. et al. Apoptosis: physiologic cell death // J. Clin. Lab. Med. - 1994. - Vol. 124. - P. 761-765.Cohen J.J., Duke R.C., Fadok V.A. et al. Apoptosis: physiologic cell death // J. Clin. Lab. Med. - 1994. - Vol. 124. - P. 761-765.Барышников А.Ю., Шишкин Ю.В. Иммунологические проблемы апоптоза. - M.: 2002. - 320 c.Барышников А.Ю., Шишкин Ю.В. Иммунологические проблемы апоптоза. - M.: 2002. - 320 c.Один В.И. Аутоиммунный сахарный диабет. - Санкт-Петербург.: 2003. - 344 с.Один В.И. Аутоиммунный сахарный диабет. - Санкт-Петербург.: 2003. - 344 с.Hale A.J., Smith C.A., Sutherland L.C. et al. Apoptosis: molecular regulation of death // Eur. J. Biochem. - 1996. - Vol. 236. - P. 1-26.Hale A.J., Smith C.A., Sutherland L.C. et al. Apoptosis: molecular regulation of death // Eur. J. Biochem. - 1996. - Vol. 236. - P. 1-26.Nagata S. Apoptosis by death factor // Cell. - 1997. - Vol. 88. - P. 355-365.Nagata S. Apoptosis by death factor // Cell. - 1997. - Vol. 88. - P. 355-365.Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO- 2L) apoptosis system // Exp. Cell Res. - 2000. - Vol. 256. - P. 58-66.Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO- 2L) apoptosis system // Exp. Cell Res. - 2000. - Vol. 256. - P. 58-66.Cnop M., Welsh N., Jonas J.C. et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities // Diabetes. - 2005. - Vol. 54 (Suppl 2). - S. 97-107.Cnop M., Welsh N., Jonas J.C. et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities // Diabetes. - 2005. - Vol. 54 (Suppl 2). - S. 97-107.Scaffidi C., Schmitz I., Zha J., Korsmeyer S.J. et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II // J. Biol. Chem. - 1999. - Vol. 274. - P. 22532-22538.Scaffidi C., Schmitz I., Zha J., Korsmeyer S.J. et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II // J. Biol. Chem. - 1999. - Vol. 274. - P. 22532-22538.Rathmell J.C., Thompson C.B. The central effectors of cell death in immune system // Annu. Rev. Immunol. - 1999. - Vol. 17. - P. 781-828.Rathmell J.C., Thompson C.B. The central effectors of cell death in immune system // Annu. Rev. Immunol. - 1999. - Vol. 17. - P. 781-828.Green D.R. Apoptotic pathways: ten minutes to dead // Cell. - 2005. - Vol. 121. - P. 671-674.Green D.R. Apoptotic pathways: ten minutes to dead // Cell. - 2005. - Vol. 121. - P. 671-674.Eguchi K. Apoptosis in autoimmune diseases // Internal. Medicine. - 2001. - Vol. 40. - P. 275-284.Eguchi K. Apoptosis in autoimmune diseases // Internal. Medicine. - 2001. - Vol. 40. - P. 275-284.Brenner C., Cadiou H., Vieira H.L. et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator // Oncogene. - 2000. - Vol. 19. - P. 329-336.Brenner C., Cadiou H., Vieira H.L. et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator // Oncogene. - 2000. - Vol. 19. - P. 329-336.Chang I., Kim S., Kim J.Y. et al. Nuclear factor ƒB protects pancreatic ƒ-cells from tumor necrosis factor-ƒ-mediated apoptosis // Diabetes. - 2003. - Vol. 52. - P. 1169-1175.Chang I., Kim S., Kim J.Y. et al. Nuclear factor ƒB protects pancreatic ƒ-cells from tumor necrosis factor-ƒ-mediated apoptosis // Diabetes. - 2003. - Vol. 52. - P. 1169-1175.Salah-Eddine, Lamhamedi-Cherradi, Zheng S. et al. Transcriptional regulation of type I diabetes by NF-кB // The Journal of Immunology. - 2003. - Vol. 171. - P. 4886-4892.Salah-Eddine, Lamhamedi-Cherradi, Zheng S. et al. Transcriptional regulation of type I diabetes by NF-кB // The Journal of Immunology. - 2003. - Vol. 171. - P. 4886-4892.Takahashi T., Tanaka M., Brannan C.I. et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand // Cell. - 1994. - Vol. 76. - P. 969-976.Takahashi T., Tanaka M., Brannan C.I. et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand // Cell. - 1994. - Vol. 76. - P. 969-976.Kabelitz D., Pohl T., Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes // Immunol. Today. - 1993. - Vol. 14. - P. 338-339.Kabelitz D., Pohl T., Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes // Immunol. Today. - 1993. - Vol. 14. - P. 338-339.Watanabe-Fukunaga R., Brannan C.I., Copeland N.G. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis // Nature. - 1992. - Vol. 356. - P. 314-317.Watanabe-Fukunaga R., Brannan C.I., Copeland N.G. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis // Nature. - 1992. - Vol. 356. - P. 314-317.Leijon K., Hammarstrљm B., Holmberg D. The non-obese diabetic (NOD) mouse displays enhanced immune responses and prolonged survival of lymphoid cells // Int. Immunol. - 1994. - №6. - P. 339-345.Leijon K., Hammarstrљm B., Holmberg D. The non-obese diabetic (NOD) mouse displays enhanced immune responses and prolonged survival of lymphoid cells // Int. Immunol. - 1994. - №6. - P. 339-345.Lamhamedi-Cherradi S.E., Luan J.J., Eloy L. et al. Resistance of T-cells to apoptosis in autoimmune diabetes NOD mice is increased early in life and is associated with dysregulation of Bcl-xL // Diabetologia. - 1998. - Vol. 41. - P. 178-184.Lamhamedi-Cherradi S.E., Luan J.J., Eloy L. et al. Resistance of T-cells to apoptosis in autoimmune diabetes NOD mice is increased early in life and is associated with dysregulation of Bcl-xL // Diabetologia. - 1998. - Vol. 41. - P. 178-184.Giordano C., De Maria R., Stassi G. et al. Defective expression of the apoptosiss-inducing CD95 (Fas/APO-1) molecule on T- and B-cells in IDDM // Diabetologia. - 1995. - Vol. 38. - P. 1449-1454.Giordano C., De Maria R., Stassi G. et al. Defective expression of the apoptosiss-inducing CD95 (Fas/APO-1) molecule on T- and B-cells in IDDM // Diabetologia. - 1995. - Vol. 38. - P. 1449-1454.Liu C.C., Young L.Y., Young J.D. Lymphocyte-mediated cytolysis and disease // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1651-1659.Liu C.C., Young L.Y., Young J.D. Lymphocyte-mediated cytolysis and disease // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1651-1659.Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM // Diabetologia. - 1996. - Vol. 39. - P. 1005-1029.Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM // Diabetologia. - 1996. - Vol. 39. - P. 1005-1029.Rutter G.A., Wong F. S. The pancreatic ƒ-cell: birth, life and death // Biochem. Soc. Trans. - 2008. - Vol. 36. - P. 267-271.Rutter G.A., Wong F. S. The pancreatic ƒ-cell: birth, life and death // Biochem. Soc. Trans. - 2008. - Vol. 36. - P. 267-271.Marselli L., Dotta F.D., Piro S. et al. Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86. - P. 4974-4978.Marselli L., Dotta F.D., Piro S. et al. Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86. - P. 4974-4978.Pirot P., Cardozo A.K., Eizirik D.L. Mediators and mechanisms of pancreatic ƒ-cell death in type 1 diabetes // Arq. Bras. Endocrinol. Metab. - 2008. - Vol. 52. - P. 156-165.Pirot P., Cardozo A.K., Eizirik D.L. Mediators and mechanisms of pancreatic ƒ-cell death in type 1 diabetes // Arq. Bras. Endocrinol. Metab. - 2008. - Vol. 52. - P. 156-165.

The authors declare that there are no conflicts of interest present.